Bardia A, Hurvitz SA, DeMichele A, Clark AS, et al. Phase I/II trial of exemestane, ribociclib, and everolimus in women with HR+/HER2- advanced breast cancer after progression on CDK4/6 inhibitors (TRINITI-1). Clin Cancer Res 2021 Mar 15. pii: 1078-0432.CCR-20-2114.
PMID: 33722897